587 related articles for article (PubMed ID: 31612694)
1. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
2. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
3. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
Lee H; Basso IN; Kim DDH
Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
[TBL] [Abstract][Full Text] [Related]
4. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
5. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
6. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence.
Ciftciler R; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):7787-7798. PubMed ID: 34982440
[TBL] [Abstract][Full Text] [Related]
7. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
8. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Shah NP
J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
[TBL] [Abstract][Full Text] [Related]
9. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
Baccarani M; Abruzzese E; Accurso V; Albano F; Annunziata M; Barulli S; Beltrami G; Bergamaschi M; Binotto G; Bocchia M; Caocci G; Capodanno I; Cavazzini F; Cedrone M; Cerrano M; Crugnola M; D'Adda M; Elena C; Fava C; Fazi P; Fozza C; Galimberti S; Giai V; Gozzini A; Gugliotta G; Iurlo A; La Barba G; Levato L; Lucchesi A; Luciano L; Lunghi F; Lunghi M; Malagola M; Marasca R; Martino B; Melpignano A; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Pregno P; Rapezzi D; Rege-Cambrin G; Rupoli S; Salvucci M; Sancetta R; Sica S; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Trabacchi E; Bonifacio M; Breccia M; Castagnetti F; Pane F; Russo D; Saglio G; Soverini S; Vigneri P; Rosti G
Blood Adv; 2019 Dec; 3(24):4280-4290. PubMed ID: 31869412
[TBL] [Abstract][Full Text] [Related]
10. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
12. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
14. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
Saglio G; Jabbour E
Leuk Lymphoma; 2018 Jul; 59(7):1523-1538. PubMed ID: 28972424
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Monitoring of Chronic Myeloid Leukemia: Chiang Mai University Experience.
Tantiworawit A; Kongjarern S; Rattarittamrong E; Lekawanvijit S; Bumroongkit K; Boonma N; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
Asian Pac J Cancer Prev; 2016; 17(4):2159-64. PubMed ID: 27221912
[TBL] [Abstract][Full Text] [Related]
16. [The importance of taking late cardiovascular toxicity induced by TKI into consideration in patients with CML].
Takahashi N
Rinsho Ketsueki; 2016; 57(10):1956-1961. PubMed ID: 27725593
[TBL] [Abstract][Full Text] [Related]
17. Is there a best TKI for chronic phase CML?
Larson RA
Blood; 2015 Nov; 126(21):2370-5. PubMed ID: 26585806
[TBL] [Abstract][Full Text] [Related]
18. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Lau A; Seiter K
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
[TBL] [Abstract][Full Text] [Related]
19. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
20. The Role of Early Molecular Response in the Management of Chronic Phase CML.
Harrington P; Kizilors A; de Lavallade H
Curr Hematol Malig Rep; 2017 Apr; 12(2):79-84. PubMed ID: 28405921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]